{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?identifier=10093&humanIndexable=true&min-date=2015-09-11", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?identifier=10093&humanIndexable=true&min-date=2015-09-11", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?identifier=10093&humanIndexable=true&min-date=2015-09-11&_metadata=all", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?identifier=10093&_page=0&humanIndexable=true&min-date=2015-09-11", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?identifier=10093&humanIndexable=true&min-date=2015-09-11", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?identifier=10093&humanIndexable=true&min-date=2015-09-11", "items" : [{"_about" : "http://data.parliament.uk/resources/1682961", "AnsweringBody" : [{"_value" : "Department for Environment, Food and Rural Affairs"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1682961/answer", "answerText" : {"_value" : "

The UK Government continues to support conservation and biodiversity projects in the Overseas Territories, through initiatives such as the Darwin Plus Programme. The programme expanded in April 2023, offering greater levels of funding for Darwin Plus projects and the UK Government committed to make available, £10 million each year until 2025 to improve the natural environment of the Overseas Territories. The programme has made available:<\/p>

<\/p>

Darwin Plus Strategic: Funding between £1m-£3m.<\/p>

Darwin Plus Main: Between £100k-£1m for projects.<\/p>

Darwin Plus Local: Up to £20k for individuals and £50k for organisations.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4522", "label" : {"_value" : "Biography information for Rebecca Pow"} } , "answeringMemberConstituency" : {"_value" : "Taunton Deane"} , "answeringMemberPrinted" : {"_value" : "Rebecca Pow"} , "dateOfAnswer" : {"_value" : "2024-02-06", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-02-06T10:18:21.293Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "13"} , "answeringDeptShortName" : {"_value" : "Environment, Food and Rural Affairs"} , "answeringDeptSortName" : {"_value" : "Environment, Food and Rural Affairs"} , "date" : {"_value" : "2024-01-17", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Darwin Plus"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Environment, Food and Rural Affairs, how much funding has been made available to each Darwin Plus project in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4006", "label" : {"_value" : "Biography information for Dr Matthew Offord"} } , "tablingMemberConstituency" : {"_value" : "Hendon"} , "tablingMemberPrinted" : [{"_value" : "Dr Matthew Offord"} ], "uin" : "10093"} , {"_about" : "http://data.parliament.uk/resources/759849", "AnsweringBody" : [{"_value" : "Department for Work and Pensions"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/759849/answer", "answerText" : {"_value" : "

I refer the hon. Member to the answer I gave on 5 September 2017 to Question UIN 6544<\/p>

http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2017-07-20/6544/<\/a><\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4017", "label" : {"_value" : "Biography information for Penny Mordaunt"} } , "answeringMemberConstituency" : {"_value" : "Portsmouth North"} , "answeringMemberPrinted" : {"_value" : "Penny Mordaunt"} , "dateOfAnswer" : {"_value" : "2017-09-18", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2017-09-18T13:52:56.54Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "29"} , "answeringDeptShortName" : {"_value" : "Work and Pensions"} , "answeringDeptSortName" : {"_value" : "Work and Pensions"} , "date" : {"_value" : "2017-09-12", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Employment and Support Allowance: Parkinson's Disease"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Work and Pensions, how many people with Parkinson's disease have been placed in the (a) support group and (b) work-related activity group with a prognosis statement (i) of three months, (ii) of six months, (iii) of 12 months, (iv) of 18 months, (v) of two years and (vi) in the longer term since the introduction of employment and support allowance in 2008; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1490", "label" : {"_value" : "Biography information for Mrs Madeleine Moon"} } , "tablingMemberConstituency" : {"_value" : "Bridgend"} , "tablingMemberPrinted" : [{"_value" : "Mrs Madeleine Moon"} ], "uin" : "10093"} , {"_about" : "http://data.parliament.uk/resources/418453", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/418453/answer", "answerText" : {"_value" : "

Neither the Department nor NHS England has made any such assessment.<\/p>

<\/p>

<\/p>

<\/p>

Advances in medical science means that new cancer medicines are emerging all the time and NHS England needs to regularly prioritise its national Cancer Drugs Fund (CDF) list so people can access these too. Decisions on which treatments are included on the list are made by the CDF expert clinical panel because it is right these decisions are clinically led.<\/p>

<\/p>

<\/p>

<\/p>

<\/p>

<\/p>

<\/strong><\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} , "dateOfAnswer" : {"_value" : "2015-09-16", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2015-09-16T15:25:30.407Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2015-09-11", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Cancer Drugs Fund"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, what assessment he has made of the effect on cancer clinical trials of NHS England's decision announced on 4 September 2015 to remove (a) Abraxane and (b) 22 other drugs and indications from the Cancer Drugs Fund list of approved drugs; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4056", "label" : {"_value" : "Biography information for Nic Dakin"} } , "tablingMemberConstituency" : {"_value" : "Scunthorpe"} , "tablingMemberPrinted" : [{"_value" : "Nic Dakin"} ], "uin" : "10093"} ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 3, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]} }